BioMarin Pharmaceutical Inc. (BM8.DE)
EUR 61.96
(-1.71%)
EUR 61.96
(-1.71%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.89 Billion USD | 6.67% |
| 2022 | 1.77 Billion USD | 2.27% |
| 2021 | 1.73 Billion USD | -0.54% |
| 2020 | 1.74 Billion USD | 11.12% |
| 2019 | 1.56 Billion USD | 7.43% |
| 2018 | 1.45 Billion USD | -20.02% |
| 2017 | 1.82 Billion USD | 45.1% |
| 2016 | 1.25 Billion USD | -5.35% |
| 2015 | 1.32 Billion USD | 38.02% |
| 2014 | 962.55 Million USD | 5.99% |
| 2013 | 908.17 Million USD | 55.01% |
| 2012 | 585.88 Million USD | 10.41% |
| 2011 | 530.63 Million USD | -2.7% |
| 2010 | 545.36 Million USD | -8.34% |
| 2009 | 594.97 Million USD | -5.56% |
| 2008 | 630.02 Million USD | 0.39% |
| 2007 | 627.55 Million USD | 81.57% |
| 2006 | 345.63 Million USD | 26.71% |
| 2005 | 272.76 Million USD | -9.36% |
| 2004 | 300.94 Million USD | 117.31% |
| 2003 | 138.48 Million USD | 1047.08% |
| 2002 | 12.07 Million USD | -1.55% |
| 2001 | 12.26 Million USD | 76.73% |
| 2000 | 6.93 Million USD | 34.16% |
| 1999 | 5.17 Million USD | 146.29% |
| 1998 | 2.1 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.79 Billion USD | -4.83% |
| 2023 Q3 | 1.86 Billion USD | 4.55% |
| 2023 Q2 | 1.78 Billion USD | 0.32% |
| 2023 Q4 | 1.89 Billion USD | 1.55% |
| 2023 FY | 1.89 Billion USD | 6.67% |
| 2023 Q1 | 1.77 Billion USD | 0.15% |
| 2022 Q4 | 1.77 Billion USD | 4.51% |
| 2022 FY | 1.77 Billion USD | 2.27% |
| 2022 Q1 | 1.67 Billion USD | -3.53% |
| 2022 Q2 | 1.64 Billion USD | -1.82% |
| 2022 Q3 | 1.69 Billion USD | 3.32% |
| 2021 Q2 | 1.65 Billion USD | 0.84% |
| 2021 FY | 1.73 Billion USD | -0.54% |
| 2021 Q3 | 1.71 Billion USD | 3.28% |
| 2021 Q4 | 1.73 Billion USD | 1.24% |
| 2021 Q1 | 1.64 Billion USD | -5.68% |
| 2020 Q1 | 1.48 Billion USD | -5.41% |
| 2020 Q3 | 2.1 Billion USD | 1.88% |
| 2020 Q4 | 1.74 Billion USD | -17.21% |
| 2020 FY | 1.74 Billion USD | 11.12% |
| 2020 Q2 | 2.06 Billion USD | 39.29% |
| 2019 Q2 | 1.43 Billion USD | -4.43% |
| 2019 Q3 | 1.48 Billion USD | 3.58% |
| 2019 Q4 | 1.56 Billion USD | 5.66% |
| 2019 FY | 1.56 Billion USD | 7.43% |
| 2019 Q1 | 1.49 Billion USD | 2.71% |
| 2018 Q4 | 1.45 Billion USD | -18.04% |
| 2018 FY | 1.45 Billion USD | -20.02% |
| 2018 Q1 | 1.78 Billion USD | -1.9% |
| 2018 Q2 | 1.73 Billion USD | -2.8% |
| 2018 Q3 | 1.78 Billion USD | 2.34% |
| 2017 Q3 | 1.76 Billion USD | 44.33% |
| 2017 Q4 | 1.82 Billion USD | 3.24% |
| 2017 Q2 | 1.22 Billion USD | 4.69% |
| 2017 Q1 | 1.16 Billion USD | -6.99% |
| 2017 FY | 1.82 Billion USD | 45.1% |
| 2016 FY | 1.25 Billion USD | -5.35% |
| 2016 Q2 | 1.16 Billion USD | -15.04% |
| 2016 Q1 | 1.37 Billion USD | 3.63% |
| 2016 Q3 | 1.19 Billion USD | 2.28% |
| 2016 Q4 | 1.25 Billion USD | 5.1% |
| 2015 Q1 | 1.23 Billion USD | 28.12% |
| 2015 Q3 | 1.33 Billion USD | 3.13% |
| 2015 Q4 | 1.32 Billion USD | -0.28% |
| 2015 FY | 1.32 Billion USD | 38.02% |
| 2015 Q2 | 1.29 Billion USD | 4.74% |
| 2014 Q4 | 962.55 Million USD | 3.28% |
| 2014 Q2 | 883.71 Million USD | 0.35% |
| 2014 Q3 | 931.99 Million USD | 5.46% |
| 2014 Q1 | 880.6 Million USD | -3.04% |
| 2014 FY | 962.55 Million USD | 5.99% |
| 2013 Q4 | 908.17 Million USD | 163.97% |
| 2013 FY | 908.17 Million USD | 55.01% |
| 2013 Q2 | 343.26 Million USD | -1.4% |
| 2013 Q3 | 344.04 Million USD | 0.23% |
| 2013 Q1 | 348.14 Million USD | -40.58% |
| 2012 Q1 | 525.13 Million USD | -1.04% |
| 2012 Q4 | 585.88 Million USD | 6.1% |
| 2012 FY | 585.88 Million USD | 10.41% |
| 2012 Q3 | 552.18 Million USD | 3.77% |
| 2012 Q2 | 532.1 Million USD | 1.33% |
| 2011 Q1 | 543.3 Million USD | -0.38% |
| 2011 Q3 | 520.53 Million USD | -5.03% |
| 2011 Q4 | 530.63 Million USD | 1.94% |
| 2011 Q2 | 548.08 Million USD | 0.88% |
| 2011 FY | 530.63 Million USD | -2.7% |
| 2010 Q1 | 620.96 Million USD | 4.37% |
| 2010 FY | 545.36 Million USD | -8.34% |
| 2010 Q4 | 545.36 Million USD | -17.23% |
| 2010 Q3 | 658.86 Million USD | 5.83% |
| 2010 Q2 | 622.55 Million USD | 0.26% |
| 2009 Q2 | 561 Million USD | -10.43% |
| 2009 Q3 | 565.5 Million USD | 0.8% |
| 2009 Q4 | 594.97 Million USD | 5.21% |
| 2009 FY | 594.97 Million USD | -5.56% |
| 2009 Q1 | 626.34 Million USD | -0.58% |
| 2008 Q3 | 621.13 Million USD | -1.18% |
| 2008 Q1 | 618.53 Million USD | -1.44% |
| 2008 FY | 630.02 Million USD | 0.39% |
| 2008 Q2 | 628.52 Million USD | 1.62% |
| 2008 Q4 | 630.02 Million USD | 1.43% |
| 2007 Q4 | 627.55 Million USD | 1.79% |
| 2007 Q2 | 614.03 Million USD | 115.41% |
| 2007 FY | 627.55 Million USD | 81.57% |
| 2007 Q1 | 285.05 Million USD | -17.53% |
| 2007 Q3 | 616.51 Million USD | 0.4% |
| 2006 Q2 | 419.82 Million USD | -5.06% |
| 2006 FY | 345.63 Million USD | 26.71% |
| 2006 Q4 | 345.63 Million USD | 0.2% |
| 2006 Q3 | 344.95 Million USD | -17.83% |
| 2006 Q1 | 442.22 Million USD | 62.13% |
| 2005 Q2 | 277.68 Million USD | 2.4% |
| 2005 Q1 | 271.16 Million USD | -9.89% |
| 2005 FY | 272.76 Million USD | -9.36% |
| 2005 Q4 | 272.76 Million USD | -0.53% |
| 2005 Q3 | 274.22 Million USD | -1.25% |
| 2004 Q3 | 298.06 Million USD | -2.02% |
| 2004 Q2 | 304.22 Million USD | 116.49% |
| 2004 Q1 | 140.52 Million USD | 1.47% |
| 2004 FY | 300.94 Million USD | 117.31% |
| 2004 Q4 | 300.94 Million USD | 0.97% |
| 2003 Q3 | 142.48 Million USD | -1.02% |
| 2003 Q4 | 138.48 Million USD | -2.8% |
| 2003 Q2 | 143.94 Million USD | 736.18% |
| 2003 Q1 | 17.21 Million USD | 42.59% |
| 2003 FY | 138.48 Million USD | 1047.08% |
| 2002 Q4 | 12.07 Million USD | 7.23% |
| 2002 Q3 | 11.25 Million USD | 0.58% |
| 2002 Q2 | 11.19 Million USD | -13.48% |
| 2002 Q1 | 12.93 Million USD | 5.5% |
| 2002 FY | 12.07 Million USD | -1.55% |
| 2001 Q4 | 12.26 Million USD | 96.65% |
| 2001 Q2 | 5.32 Million USD | 44.44% |
| 2001 FY | 12.26 Million USD | 76.73% |
| 2001 Q1 | 3.68 Million USD | -46.91% |
| 2001 Q3 | 6.23 Million USD | 17.2% |
| 2000 FY | 6.93 Million USD | 34.16% |
| 2000 Q4 | 6.93 Million USD | 88.97% |
| 2000 Q3 | 3.67 Million USD | 26.88% |
| 2000 Q2 | 2.89 Million USD | -39.19% |
| 2000 Q1 | 4.75 Million USD | -7.99% |
| 1999 Q4 | 5.17 Million USD | -9.26% |
| 1999 FY | 5.17 Million USD | 146.29% |
| 1999 Q2 | 34 Million USD | 1900.0% |
| 1999 Q1 | 1.7 Million USD | 0.0% |
| 1999 Q3 | 5.7 Million USD | -83.24% |
| 1998 FY | 2.1 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| BioNTech SE | 2.76 Billion EUR | 31.53% |
| CureVac N.V. | 271.53 Million EUR | -596.071% |
| Biotest Aktiengesellschaft | 945.4 Million EUR | -99.921% |
| Biotest Aktiengesellschaft | 945.4 Million EUR | -99.921% |
| BRAIN Biotech AG | 47.92 Million EUR | -3843.939% |
| Formycon AG | 387.61 Million EUR | -387.616% |
| Heidelberg Pharma AG | 21.01 Million EUR | -8894.588% |
| Medigene AG | 10.65 Million EUR | -17646.986% |